Myconormin (Terbinafine Hydrochloride)

Terbinafine hydrochloride inhibits the fungal enzyme squalene epoxidase, which is essential for synthesising ergosterol, a key component of fungal cell membranes. Blocking this step leads to toxic squalene buildup and loss of membrane integrity, ultimately killing the fungal cells and halting infection.

The specific dosage of Myconormin is determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Healthcare providers set the appropriate regimen and duration according to current clinical guidelines.

Safety data for terbinafine during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should evaluate each case individually and discuss alternatives when appropriate.

To request Myconormin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine offers a different mechanism by targeting squalene epoxidase, often resulting in shorter treatment courses for nail infections. It may have fewer drug‑drug interactions than some azoles but requires monitoring for liver function and potential skin reactions.

Myconormin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency throughout its shelf life.

Myconormin is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow the dosing schedule provided by their healthcare professional.

Serious risks include hepatotoxicity, which may present as elevated liver enzymes or hepatitis, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if signs of liver dysfunction or severe rash develop.

Myconormin is contraindicated in individuals with known hypersensitivity to terbinafine or any component of the formulation. Caution is also advised for patients with pre‑existing liver disease, and it should be avoided in pregnant or breastfeeding women unless clearly indicated by a physician.